Limbus Medical Technologies has acquired German genomics company Nostos Genomics, known for its CE-IVD certified Aion genetic variant interpretation platform. The acquisition aims to complement Limbus’s existing Varvis clinical diagnostic decision support system, enhancing clinicians’ ability to interpret rare disease genomics data. Both companies will operate independently but plan integration of the Aion platform into Varvis. This strategic move strengthens Limbus’s position in the genomics software market, supporting precision medicine and clinical decision-making for complex genetic disorders.